Simon Brežan MD (@BrezanSimonMD) profile picture

MD/ dr. med. Medical counseling Cognitive neuroscientist, systems neuroscience, complex systems, EEG synchronization, cognition, enactivism, longevity/biohack

Joined March 2020
Photo by Simon Brežan MD (@BrezanSimonMD)Photo by Simon Brežan MD (@BrezanSimonMD)Photo by Simon Brežan MD (@BrezanSimonMD)Photo by Simon Brežan MD (@BrezanSimonMD)Photo by Simon Brežan MD (@BrezanSimonMD)Photo by Simon Brežan MD (@BrezanSimonMD)Photo by Simon Brežan MD (@BrezanSimonMD)Photo by Simon Brežan MD (@BrezanSimonMD)Photo by Simon Brežan MD (@BrezanSimonMD)Photo by Simon Brežan MD (@BrezanSimonMD)
Simon Brežan MD retweeted
👉THE FORGOTTEN RESIDUAL RISK: LIFETIME CHOLESTEROL EXPOSURE 👆We keep searching for residual inflammatory risk and other pathways. But are we overlooking the most obvious one? 1⃣ Cardiovascular risk reflects not only today's LDL-C level, but decades of cumulative cholesterol exposure. 2⃣ Supraphysiological LDL-C levels have consequences; maintaining elevated LDL-C concentrations for decades drives progressive cholesterol accumulation within the arterial wall. 3⃣ We focus on inflammation and other mechanisms; but we may underestimate the lasting consequences of decades of excessive LDL-C exposure. 4⃣ Five years (a trial duration) cannot erase fifty; intensive LDL-C lowering reduces future exposure, but cannot undo the entire atherogenic burden accumulated over a lifetime. 5⃣ The legacy effect is real; earlier LDL-C lowering can provide sustained cardiovascular benefits, even when LDL-C levels subsequently become similar between treatment groups. 👆 The key question is not just HOW LOW LDL-C is today, but HOW LONG it has been low. 👉 The most overlooked component of residual cardiovascular risk is the cholesterol exposure we failed to prevent. @society_eas
🤖 Made with AI
12
51
4
188
11,032
Simon Brežan MD retweeted
Prevention of heart failure: A scientific statement of the Heart Failure Association, the European Association of Preventive Cardiology, and the Association of Cardiovascular Nursing & Allied Professions of the ESC, and the ESC Council on Hypertension Heart failure prevention starts long before heart failure develops. 🫀 A new ESC scientific statement emphasizes a major shift: identify risk early and act before structural heart disease becomes symptomatic. And prevention starts with lifestyle. Ultra-processed foods promote obesity, hypertension, dyslipidaemia, diabetes, CKD and inflammation — pathways ultimately linked to HF, arrhythmias, cardiovascular disease and mortality. 👉 In 2026, asking our patients what they eat should be part of cardiovascular risk assessment. Prevent early. Treat risk factors aggressively. Protect the heart before it fails. #HeartFailure #Prevention #ESC #Cardiology #Nutrition #CardiovascularPrevention #HealthyLifestyle academic.oup.com/eurheartj/a…
2
17
1
41
6,224
Simon Brežan MD retweeted
Hi all, The Lp(a) HORIZON trial has released topline data and, quite shockingly, missed its primary endpoint. In other words, lowering Lp(a) in patients with prior MI, stroke or peripheral arterial disease, who were otherwise very well treated for LDL-C, blood pressure, diabetes and other risk factors, did not reduce the primary cardiovascular endpoint. We obviously need to see the full data before making firm conclusions, and I don’t want to speculate too much without the details. But this is a big enough result that it is worth summarizing what we know, what we don’t know, and what this may mean for our patients after 20+ years of trying to test the “Lp(a) hypothesis.” What we know: 1-There are hundreds if not thousands of genetic, epidemiologic and Mendelian-randomization studies showing that elevated Lp(a) is associated with MI, stroke, peripheral arterial disease and aortic stenosis. That body of evidence is very strong. 2-However, much of those data come from community-based populations, often before the era of intensive LDL-C lowering and modern secondary prevention. 3-There has been much less information about how much residual risk Lp(a) carries in someone who has already had an event and is then treated very aggressively. 4-HORIZON may have had some of the best-treated patients of any recent cardiovascular outcomes trial. Baseline LDL-C was about 65 mg/dL, a measured LDL-C contains the cholesterol carried on Lp(a), so in reality, 15-20 points lower. 5-In patients with very high Lp(a), if you correct LDL-C for Lp(a)-cholesterol, the actual LDL-C carried by LDL particles may have been closer to 45–50 mg/dL, perhaps even lower in some patients. 6-This raises a very basic question: Can you still demonstrate a major incremental benefit from lowering another apoB-containing particle when the underlying LDL burden has already been driven this low? What we don’t know: 1-What was the actual corrected LDL-C in these patients? I think it would be extremely informative to directly measure Lp(a)-C and calculate corrected LDL-C. This may tell us a lot about the biological setting in which pelacarsen was being tested. 2- What was the OxPL status? Our prior work has suggested that much of the pro-inflammatory biology associated with Lp(a) is related to its enrichment in oxidized phospholipids. Did OxPL fall? Did patients with higher OxPL derive more benefit? Was Lp(a) concentration actually identifying the patients with the most pathogenic particles? 3- Did we measure the right component of Lp(a) for trial inclusion? We generally measure molar particle concentration. But is molar concentration itself the main driver of risk, or is it partly a surrogate for what the particle carries? Cholesterol? Triglycerides? Oxidized phospholipids? Other proteins? Could two patients with the same Lp(a) concentration have very different Lp(a)-mediated risk? I think this question deserves much more attention. 3- Were the genetic data telling us exactly what we thought they were telling us? The genetic data are extremely compelling, but genetics reflect lifelong exposure. A clinical trial treats patients late in life, often after decades of arterial injury and after an event has already occurred. Those are not necessarily the same experiment. Could there also be some unrecognized biology linked to the LPA locus that we have not completely accounted for? That possibility should at least be considered. 3- Does very low LDL-C modify the Lp(a) risk relationship? Maybe Lp(a) is particularly important when LDL-C is higher, but its contribution becomes smaller once LDL-C is driven to very low levels. Again, we need the data. 4- Does aspirin or other antiplatelet therapy reduce part of the risk associated with Lp(a)? Lp(a) has potentially important prothrombotic effects. Almost everyone in a trial like HORIZON is receiving contemporary antiplatelet therapy. Could that blunt one component of the risk associated with Lp(a)? 5- Why are these patients still having events? This may be one of the most interesting questions of all. These are patients with LDL-C around 65 mg/dL, and perhaps corrected LDL-C substantially lower, yet cardiovascular events continue to occur. What is driving that residual risk? Inflammation? Thrombosis? Plaque burden that is already too advanced? Other lipoprotein characteristics? Something we are not measuring? 6- Do we need to re-examine some basic assumptions about atherosclerosis? We have spent decades focusing heavily on the quantity of circulating lipoproteins. But perhaps lipoproteins are relatively benign until they undergo biological modification in the artery wall. Oxidation may be one of those key modifications. For some patients, the answer may be to remove more particles from the circulation. For others, perhaps the better approach is to prevent their oxidation or block the downstream biological effects of oxidized lipids. The recent difficulties with anti-inflammatory approaches, including IL-6 inhibition, make these mechanistic questions even more interesting. 7- Was there something specific about pelacarsen, the degree or timing of Lp(a) lowering, advanced disease, trial duration, background therapy or patient selection that mitigated a potential benefit? We simply don’t know yet. That is why the detailed results will be so important. What does this mean for patients today? If you have already had an MI, stroke or PAD, the immediate lesson is very clear: 1- Get all of your established risk factors treated aggressively. 2- Get LDL-C/apoB very low. 3- Control blood pressure. 4- Control diabetes. 5- Don’t smoke. 6- Use appropriate antiplatelet and other guideline-directed therapies. HORIZON shows us what modern secondary prevention should look like. If you have elevated Lp(a) but have never had an event, the genetic and epidemiologic data still suggest increased lifetime risk. Until the other 4 outcome trials read out, I would continue to treat every modifiable risk factor aggressively. We should wait for those trials before drawing broad conclusions about the entire field. I think the story of Lp(a) therapy is beginning, not ending. We also need to show tremendous respect and gratitude to the patients who participated in HORIZON and to the investigators and companies that invested enormous resources to actually test the Lp(a) hypothesis, to the ultimate benefit to peole with elevated Lp(a) to best guide how to manage risk. More to come as we go forward.
95
311
43
1,093
183,348
The good news here is, to prove yet another time to denialists and conspiracy theorists: yes, also negative clinical trials are published in serious evidence based science / medicine. Although, as always, even more can be done in this respect...
I’m a cardiologist. Today cardiologists everywhere were humbled by this trial. The trial is Lp(a)HORIZON. Pelacarsen, a monthly antisense injection from Novartis and Ionis, was given to 8,323 patients who already had heart disease plus genetically high lipoprotein(a). These were not untreated people. They were on modern guideline therapy—high-intensity statins, blood-pressure control, antiplatelets. The drug did its job: it slashed Lp(a) levels by roughly 70–80%, the same drop we saw in earlier studies. The thing it was supposed to prevent did not move. Cardiovascular death, heart attack, stroke, and urgent stents or bypasses were no lower than placebo. The miss held even in the sicker subgroup whose Lp(a) started above 90 mg/dL. That is why the field is in shock. For a decade we treated this as settled biology. Lp(a) is 80–90% genetic. One in five adults carry high levels. Diet and gym do almost nothing. Observational studies and Mendelian randomization kept saying the same thing: higher lifetime Lp(a) means more heart attacks, more strokes, more aortic stenosis. Phase 2 looked like a home run—an 80% reduction with a simple monthly shot. We told ourselves this was the missing piece for the patient who already has perfect LDL, perfect blood pressure, doesn’t smoke, and still has events. Many of us expected it to be as important as the arrival of statins. Companies spent years educating the entire cardiology community that we finally had a target we could actually hit. We were wrong about the simple version of the story. A lifetime of high Lp(a) from birth is not the same experiment as turning the number down for a few years after the arteries are already damaged and every other risk factor is already optimized. Residual risk from Lp(a) may simply be smaller once LDL is already in the 40s. Eighty percent lower may still leave too much particle in people who started very high. The next drugs (siRNAs) go deeper and last longer; this was the first-generation ASO. Benefit, if it exists, might live in younger patients, primary prevention, or extreme levels rather than this secondary-prevention population. Or the effect on existing plaque and thrombosis is slower and smaller than the genetics made us believe. We will get the full event curves, actual achieved levels, and every subgroup later this year. Other outcome trials with more potent agents are still running. The Lp(a) chapter is not closed. But the version we all believed—“lower this inherited number and events will follow in already-treated patients”—just failed its first large, hard test. Measure Lp(a) once. Treat everything else we can actually change as if it still matters. Because today we learned, again, that a beautiful lab change is not the same thing as fewer funerals. Science is supposed to surprise us. This one did.
148
Lp(a) #HORIZON breaking news phase 3 results of #Pelacarsen drug 😐 #ASCVD #LLT #LpA
Lp(a)HORIZON is negative. Does this mean the Lp(a) hypothesis is wrong? I don’t think we can conclude that — at least not yet. Before seeing the full data, several explanations deserve consideration: 1. Background therapy matters. In contemporary secondary prevention, aggressive LDL-C/ApoB lowering and comprehensive risk-factor control may substantially reduce the residual risk attributable to Lp(a) 2. Perhaps we are treating too late. Genetics reflects lifelong exposure to elevated Lp(a). Lowering Lp(a) for a few years after ASCVD is already established may simply be too little, too late 3. Magnitude and duration of Lp(a) lowering may matter. Not all Lp(a)-lowering strategies are equivalent. We need the achieved absolute levels, sustained reduction, adherence, and exposure over time before extrapolating HORIZON to the entire therapeutic class 4. The benefit may lie in the extreme tail. Perhaps the clinically modifiable risk is concentrated among patients with very high Lp(a). The prespecified analyses at higher baseline Lp(a) levels will be particularly important 5. Lp(a) concentration may not tell the whole biological story. OxPL burden, apo(a) isoform size, and particle composition may influence pathogenicity. Two patients with the same Lp(a) concentration may not necessarily carry the same Lp(a)-mediated risk 6. Could the endpoint dilute the signal? Lp(a) may preferentially affect coronary and recurrent events. Individual MI/revascularization and total-event analyses may tell a different story than first 4-point MACE. 7. Genetics may predict causality better than therapeutic effect size. Mendelian randomization reflects decades of exposure. It should not automatically be translated into the magnitude of benefit expected from a relatively short pharmacological intervention 8. Are we targeting Lp(a), but not necessarily its most pathogenic cargo? Lp(a) is the major carrier of oxidized phospholipids (OxPL), which contribute to vascular inflammation, plaque vulnerability and thrombogenicity. Lp(a) concentration may therefore be an imperfect surrogate for its biological activity. The relationship between Lp(a) lowering, OxPL reduction and clinical benefit deserves particular attention 9. Could intensive antiplatelet therapy attenuate the atherothrombotic component of Lp(a) risk? Lp(a) may promote thrombosis through platelet activation, coagulation and formation of more lysis-resistant clots. OxPL can also interact with platelet receptors. In a secondary-prevention population such as HORIZON, where aspirin and other antiplatelet therapies are extensively used, part of this pathway may already be pharmacologically suppressed — potentially leaving less Lp(a)-mediated risk for pelacarsen to modify 10. Low event rates may be part of the answer. Despite enrolling 8,323 high-risk secondary-prevention patients, HORIZON required a remarkably long follow-up to accrue the prespecified number of events. This suggests that contemporary secondary prevention substantially reduced the absolute residual risk available for Lp(a) lowering to modify. Nuestro análisis previo ya señalaba que la menor tasa de eventos era una de las principales amenazas para el estudio 11. Was HORIZON powered for a larger effect than the true pharmacological effect? An event-driven design protects statistical power if the required number of events is reached — but only for the effect size assumed in the design. If short-term pharmacological Lp(a) lowering produces a much smaller benefit than predicted from lifelong genetic exposure, even a trial of >8,000 patients may struggle to demonstrate it 12. The long time required to reach the endpoint may itself be biologically informative. These were patients with established ASCVD and very high Lp(a), yet events accumulated more slowly than anticipated. Perhaps elevated Lp(a) identifies substantial lifetime risk, but contributes less modifiable short-term residual risk once other major pathways are aggressively treated. 13. Six years is a long time for background therapy to evolve. During prolonged follow-up, increasing use of PCSK9 inhibitors, ezetimibe, bempedoic acid, inclisiran, SGLT2 inhibitors and GLP-1 receptor agonists — together with improved BP and antithrombotic management — may have progressively reduced event rates in both groups. These potential therapeutic “drop-ins” were already a concern before the results were known 14. First events may not capture the entire Lp(a) burden. Lp(a) could influence recurrent coronary events and total atherosclerotic burden more strongly than time-to-first MACE. Analyses of total/recurrent events will therefore be particularly important 15. The “risk-factor exhaustion” hypothesis. With LDL-C around 65 mg/dL, intensive lipid-lowering therapy, antiplatelet treatment, good BP control and contemporary diabetes therapy, multiple atherogenic and thrombotic pathways were already being targeted. HORIZON may therefore have tested Lp(a) lowering in a setting where relatively little modifiable residual risk remained. The published baseline characteristics already showed how intensively treated this population was 16. Perhaps the effect of Lp(a) depends on the surrounding biological environment. The clinical consequences of Lp(a) may result from the interaction of apoB particle burden + OxPL-mediated inflammation + thrombosis/impaired fibrinolysis. With LDL/ApoB aggressively lowered and most patients receiving antiplatelet therapy, two important components of that environment may already have been attenuated. Maybe the key question is not simply whether Lp(a) is causal, but WHEN, in WHOM, and HOW MUCH it needs to be lowered to change clinical outcomes. Until we see the full HORIZON dataset, declaring the Lp(a) hypothesis dead seems premature. #Lp(a) #LipoproteinA #ASCVD #Cardiology #Atherosclerosis #Horizontes novartis.com/news/media-rele…
1
229
Simon Brežan MD retweeted
🫀 Statins for primary prevention: 4 RCTs, 3 decades AFCAPS→JUPITER→HOPE-3→STAREE 📉 24–44% ↓ major CV events Even at baseline LDL (108 mg/dL) No heterogeneity across subgroups in RRR 
🟰 Safety ≈ placebo, few exceptions 
⚖️ Benefits ≫ risks 💊 cost $30/year
12
86
3
278
21,993
No big surprise, so yes, act early asap to get apoB below 70 in primary prev & below 50 in sec. prev ! #apoB #LDL #LLT #CVD #statins etc etc
A statin at 70 cut heart attacks and strokes by 30% in 9,971 healthy people, yet the gain in years free of dementia and disability was small enough to be chance. A second @NEJM trial the same week shows why. REACT imaged 16,808 adults with no heart diagnosis and found silent plaque in 57%. Nine in 10 at ages 60 to 70. Already 1 in 13 at 18 to 29. By 70 the plaque has been building for decades, so the first pill arrived in the final stretch of the disease. The particles that build it, apoB, can be counted on a routine blood test, and in 4,366 young adults risk stayed lowest with apoB under about 75 mg/dL. If you're under 40, ask for that test even if your cholesterol looks normal.
5
8
1,245
Simon Brežan MD retweeted
Intensive LDL-C lowering to ~45mg/dL w/#evolocumab reduced first MIs by 36% among patients without prior CV events from VESALIUS-CV. MIs were reduced within the first six months. The findings support plaque stabilization as the principal biological mechanism @bohula #ESCCongress
2
33
5
128
8,407
Simon Brežan MD retweeted
☝️Atherosclerosis starts earlier than we think 👉New data from the REACT study, published in NEJM, provide a striking picture of silent atherosclerosis across adult life: 1️⃣ 16,808 adults, aged 18–70 years, without known ASCVD. 2️⃣ Multimodal imaging included 3D carotid and femoral ultrasound plus coronary CT angiography. 3️⃣ Silent atherosclerosis was present in 57.1% of participants. 4️⃣ Even at 18–29 years, plaque was already present in 8.7% of men and 6.7% of women. 5️⃣ By age 30–39, prevalence reached 34.6% in men and 21.3% in women. 6️⃣Atherosclerosis appeared 5–10 years earlier in men, while women showed a later but steeper rise in midlife. 7️⃣ In younger adults, disease was usually peripheral and single-territory, especially carotid; with age, plaque burden increased exponentially and disease became increasingly multiterritorial. 8️⃣ ☝️Importantly, CAC = 0 did not exclude coronary plaque: among 30–39-year-olds with coronary atherosclerosis, ~42% of men and ~48% of women had zero coronary calcium 9️⃣ SCORE2 showed major discordance with actual disease burden: high SCORE2 had only 1.9% sensitivity for silent atherosclerosis. ☝️Key message: low short-term cardiovascular risk does not mean absence of atherosclerosis. 👉Risk scores estimate events. Imaging detects disease. REACT reminds us that prevention should begin long before cardiovascular risk becomes “high.” 🔗 nejm.org/doi/full/10.1056/NE… @society_eas
22
182
16
515
107,392
Simon Brežan MD retweeted
Silent atherosclerosis can start early in life and follows patterns by age and sex throughout the lifespan, from a large cohort of >16,000 participants age 18-70 years #ESCCongress @NEJM nejm.org/doi/full/10.1056/NE…
12
95
10
393
42,387
Simon Brežan MD retweeted
👉Just published in @NEJM: STAREE Trial ☝️At last, robust randomized evidence on statins for primary prevention in older adults. 🔹 9,971 adults ≥70 years, without cardiovascular disease, diabetes, or dementia 🔹 Atorvastatin 40 mg vs placebo 🔹 Median follow-up: 5.9 years 🔹 Baseline LDL-C: ~127 mg/dL NEJMoa2607314.pdf 👉Key findings: 🔹 30% reduction in major cardiovascular events HR 0.70 (95% CI 0.61–0.82; P<0.001) 🔹 NNT = 37 over 5.9 years 🔹 MI: HR 0.57 🔹 Coronary revascularization: HR 0.57 🔹 Benefit was also observed in participants ≥75 years 👉Importantly: 🔹 No increase in dementia (HR 1.03) 🔹 No significant effect on all-cause mortality 🔹 No improvement in overall disability-free survival 🔹 Serious adverse events were similar between groups. ☝️Bottom line: Age alone should not be a reason to withhold LDL-C lowering. Even in healthy adults ≥70 years, lowering LDL-C translates into substantial cardiovascular benefit. @society_eas @nationallipid 🔗nejm.org/doi/full/10.1056/NE…
38
253
30
743
397,148
Simon Brežan MD retweeted
The majority of CKD cases in CKM syndrome are attributable to diabetes, hypertension, and other metabolic risk factors. However, kidney-protective therapies such as angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and sodium glucose cotransporter 2 inhibitors have demonstrated kidney and cardiovascular benefits for patients with CKD from metabolic etiologies as well as from some other causes. Therefore, the CKM staging construct is relevant for all patients with CKD. professional.heart.org/en/sc… ✍🏼 @ChiadiNdumele @HeartDocSadiya @kardiologykazi @noshreza @virani_md @biykemb @NutritionHF @mandeepbajaj65 @KatherineTuttl8 @RangaswJ @lisaVWMD @KBreathettMD @EmoryFamMed @ShoaClarke @mad_sters @jmortonmd @sripalbangalore @AnumSaeedMD
2
42
101
5,105
Simon Brežan MD retweeted
🚨 If LDL causes heart disease, why don't your veins ever get it. This is the "gotcha" question wellness influencers love to ask. But it does not expose a flaw in the LDL theory. It exposes a gap in their anatomy knowledge. And no, they are not just "the same tube with different jobs." I am a cardiologist. I have spent years explaining vascular biology to patients who got scared off statins by a Instagram slide. Here is what the science actually says. 🩺 The pressure difference alone should end this argument. Arteries operate at 120/80 mmHg. Veins operate under about 10 mmHg. That is not a small gap. That is an entirely different mechanical environment. 🔬 Shear stress determines where plaque forms. Malek AM et al., JAMA 1999: atherosclerosis develops at sites of low or oscillatory shear stress, around ±4 dyne per cm². Protected arterial regions run above 12 dyne per cm². High laminar shear stress is not the villain. It is protective. 🔬 Arterial and venous endothelium respond to LDL completely differently. Deng DX et al., Circulation Research 2006: when exposed to oxidized LDL, arterial endothelial cells activate far more genes for inflammation, adhesion, and apoptosis than venous cells. Same LDL. Different biological response. 🔬 Smooth muscle cells behave differently too. Faries PL et al., Journal of Surgical Research 2002: smooth muscle cells from atherosclerotic arteries proliferate, adhere, and migrate significantly more than venous smooth muscle cells. Plaque formation requires that proliferative behavior. Veins were never built for it. 💓 Here is the mechanism that matters most: retention. Arteries retain LDL particles in the vessel wall. Veins do not. That retention is the central driver of ASCVD. Not exposure. Retention. 🫀 CABG proves the point instead of disproving it. Take a healthy vein and place it into arterial circulation and watch what happens. Ward AO et al., Atherosclerosis 2017: venous endothelial cells exposed to acute arterial shear stress switch on pro-inflammatory MAPK and NF-κB signaling instead of their normal protective programs. Motwani JG and Topol EJ, Circulation 1998, and Harskamp RE et al., Annals of Surgery 2013: up to 20% of saphenous vein grafts occlude within the first year after CABG. By 10 years, about 40% are completely blocked and another 50% show advanced atherosclerotic changes. That is the real story. Put a vein into an arterial environment and it "arterializes." It starts retaining LDL. It develops the exact disease people claim veins are immune to. ⚠️ This is why the gotcha question falls apart. Veins are not protected because LDL is harmless. Veins are protected because they lack the pressure, the shear stress pattern, and the retention biology that arteries have. ❤️ Bottom line: Veins do not get atherosclerosis because they are structurally, hemodynamically, and molecularly different from arteries. It is not because LDL is irrelevant. The evidence spans decades of vascular biology research and confirms itself every time a vein graft fails in an arterial position. Get your LDL-C to target. For patients with vein grafts after CABG, that likely means below 55 or even 40 mg/dL. Control blood pressure. Control glucose. Understand that plaque location is determined by both systemic risk and local hemodynamics. A patient who gets LDL-C under 55 mg/dL after CABG can meaningfully slow graft failure over the following decade. That is the difference between a second bypass and a graft that lasts. The question is no longer "why don't veins get atherosclerosis." The question is why anyone thought that was evidence against LDL in the first place. #Cardiology #HeartDisease #HeartHealth #CardiovascularHealth #LDL #Atherosclerosis #Statins #Cholesterol #PreventiveCardiology #LifestyleMedicine
3
6
21
1,881
Simon Brežan MD retweeted
How does psilocybin alter consciousness to create a profound sense of ‘oneness’? A new study found a "hidden order" in brain activity, where networks responsible for the self and the world integrated. spklr.io/6018ERU4n
12
66
5
276
24,321
Simon Brežan MD retweeted
The mRNA vaccine success vs melanoma in a Phase definitive 3 randomized trial today is on top of signs of success for personalized mRNA neoantigen vaccines vs pancreatic cancer, triple negative breast cancer, and non-small cell lung cancer wsj.com/health/pharma/modern…
425
2,153
266
11,032
1,530,370
Simon Brežan MD retweeted
Cholesterol Paradox: Myth or Reality? •⁠ ⁠A study included 4.47 million US veterans with long-term follow-up. •⁠ ⁠The cholesterol paradox was largely explained by reverse causality, especially in older adults. •⁠ ⁠After full adjustment, higher cholesterol not lower cholesterol predicted higher CHD mortality. •⁠ ⁠The findings were consistent regardless of statin use or baseline heart disease. •⁠ ⁠Conclusion: The "cholesterol paradox" is largely an artifact of reverse causality. ahajournals.org/doi/10.1161/… @DrNadolsky @DrKarlNadolsky @NutritionMadeS3 @drmatthewnagra @MichaelAlbertMD @maciejbanach
3
3
17
1,432
The % of people with Ischemic Heart Disease has been cut almost in half since 1990. Progress in smoking prevention, blood pressure and lipid management, among others, payed off. Further progress will involve addressing obesity, type 2 diabetes, lp(a) jacc.org/doi/10.1016/j.jacc.…
6
12
3
106
15,499